With the positive sentiment in the domestic market, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Pharma India Ltd broke its 52-week high today. With the surge in the stock’s price of AstraZeneca, it was touched a new 52-week high of 1,395.00 after breaking its previous high of 1,278.00 from November 07, 2017.
Many expert analysts recommended investing in the AstraZeneca. Even in the first quarter, AstraZeneca’s sales were boosted by the launch of new products and newer medicines. AstraZeneca expects to return to growth in fiscal 2018. In the Q1, gross margin narrowed by five percentage YoY to 77.3 percent due to the favorable situation of manufacturing variances realized by the company in Q1 2017.
Given the circumstances and new innovative strategies, the company’s growth is expected to rise again in the future.